{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Elicio Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"ELTX"},"Address":{"label":"Address","value":"51 CHARLES LINDBERGH BOULEVARD, UNIONDALE, New York, 11553, United States"},"Phone":{"label":"Phone","value":"+1 415 655-4899"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Elicio Therapeutics, Inc., formerly Angion Biomedica Corp., is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer and other diseases. It provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Company's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). The Company is also evaluating the use of ELI-004, a universal AMP-modified clinical practice guidelines (CpG) adjuvant to treat or prevent additional diseases. The Company provides anaplastic lymphoma kinase (ALK) program to identify an internal development candidate. The Company conducts assessments for using ELI-004 to induce immune responses targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."},"CompanyUrl":{"label":"Company Url","value":"https://www.elicio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Christopher M. Haqq","title":"Chief Medical Officer, EVP & Head-Research"},{"name":"Esther Welkowsky","title":"Senior Vice President-Clinical Development"},{"name":"Peter DeMuth","title":"Chief Scientific Officer"},{"name":"Robert T. Connelly","title":"President, CEO, CFO, Director & CAO"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}